-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $80

Benzinga·05/11/2026 12:29:35
Listen to the news
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $95 to $80.